The “Binimetinib, Encorafenib, and Cetuximab Combined to Treat BRAF-Mutant Colorectal Cancer” BEACON CRC trial was a randomized, open-label, 3-arm phase III global study assessing triplet therapy with encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab or doublet with encorafenib plus cetuximab vs. irinotecan plus cetuximab or FOLFIRI plus cetuximab in BRAFV600E mutant mCRC patients progressing after one or two previous regimens. The gene discussed is MAP2K7; the disease is colorectal carcinoma.